A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group

on behalf of the Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group, Francesco Marchesi, Chiara Cattaneo, Marianna Criscuolo, Mario Delia, Michelina Dargenio, Maria Ilaria Del Principe, Antonio Spadea, Nicola Stefano Fracchiolla, Lorella Melillo, Katia Perruccio, Caterina Alati, Domenico Russo, Mariagrazia Garzia, Marco Brociner, Mariagiovanna Cefalo, Daniele Armiento, Simone Cesaro, Nunzia Decembrino, Andrea MengarelliMario Tumbarello, Alessandro Busca, Livio Pagano

Research output: Contribution to journalArticle

Abstract

Bronchoalveolar lavage (BAL) is recommended for diagnosing lung infiltrates (LI) in patients with hematologic malignancy (HM). Prospective data on the impact of BAL on survival are still lacking. We conducted a prospective observational study on patients who performed BAL for LI among 3055 HM patients hospitalized from January to September 2018. The BAL was performed in 145 out of 434 patients who developed LI, at a median time of four days from LI detection. The median age was 60 (1-83). Most patients had an acute myeloid leukemia/myelodisplastic syndrome (81), followed by lymphoma (41), acute lymphoblastic leukemia (27), and other types of HM (36). A putative causal agent was detected in 111 cases (76%), and in 89 cases (61%) the BAL results provided guidance to antimicrobial treatment. We observed a significantly improved outcome of LI at day +30 in patients who could receive a BAL-driven antimicrobial treatment (improvement/resolution rate: 71% vs 55%; P =.04). Moreover, we observed a significantly improved outcome in 120-day overall survival (120d-OS) (78% vs 59%; P =.009) and 120-day attributable mortality (120d-AM) (11% vs 30%; P = 0.003) for patients who could receive a BAL-driven treatment. The multivariate analysis showed that BAL-driven antimicrobial treatment was significantly associated with better 120d-OS and lower 120d-AM. We did not observe any severe adverse events. In conclusion BAL allows detection of a putative agent of LI in about 75% of cases, it is feasible and well tolerated in most cases, demonstrating that a BAL-driven antimicrobial treatment allows improvement of clinical outcome and survival.

Original languageEnglish
Pages (from-to)1104-1112
JournalAmerican Journal of Hematology
Volume94
Issue number10
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Bronchoalveolar Lavage
Hematologic Neoplasms
Multicenter Studies
Prospective Studies
Lung
Survival
Therapeutics
Mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Observational Studies
Lymphoma
Multivariate Analysis

ASJC Scopus subject areas

  • Hematology

Cite this

A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates : A prospective multicenter study of the SEIFEM group. / on behalf of the Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group ; Marchesi, Francesco; Cattaneo, Chiara; Criscuolo, Marianna; Delia, Mario; Dargenio, Michelina; Del Principe, Maria Ilaria; Spadea, Antonio; Fracchiolla, Nicola Stefano; Melillo, Lorella; Perruccio, Katia; Alati, Caterina; Russo, Domenico; Garzia, Mariagrazia; Brociner, Marco; Cefalo, Mariagiovanna; Armiento, Daniele; Cesaro, Simone; Decembrino, Nunzia; Mengarelli, Andrea; Tumbarello, Mario; Busca, Alessandro; Pagano, Livio.

In: American Journal of Hematology, Vol. 94, No. 10, 01.01.2019, p. 1104-1112.

Research output: Contribution to journalArticle

on behalf of the Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group, Marchesi, F, Cattaneo, C, Criscuolo, M, Delia, M, Dargenio, M, Del Principe, MI, Spadea, A, Fracchiolla, NS, Melillo, L, Perruccio, K, Alati, C, Russo, D, Garzia, M, Brociner, M, Cefalo, M, Armiento, D, Cesaro, S, Decembrino, N, Mengarelli, A, Tumbarello, M, Busca, A & Pagano, L 2019, 'A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group', American Journal of Hematology, vol. 94, no. 10, pp. 1104-1112. https://doi.org/10.1002/ajh.25585
on behalf of the Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group ; Marchesi, Francesco ; Cattaneo, Chiara ; Criscuolo, Marianna ; Delia, Mario ; Dargenio, Michelina ; Del Principe, Maria Ilaria ; Spadea, Antonio ; Fracchiolla, Nicola Stefano ; Melillo, Lorella ; Perruccio, Katia ; Alati, Caterina ; Russo, Domenico ; Garzia, Mariagrazia ; Brociner, Marco ; Cefalo, Mariagiovanna ; Armiento, Daniele ; Cesaro, Simone ; Decembrino, Nunzia ; Mengarelli, Andrea ; Tumbarello, Mario ; Busca, Alessandro ; Pagano, Livio. / A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates : A prospective multicenter study of the SEIFEM group. In: American Journal of Hematology. 2019 ; Vol. 94, No. 10. pp. 1104-1112.
@article{f6ec09623fd44151b083a1680d1790fc,
title = "A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group",
abstract = "Bronchoalveolar lavage (BAL) is recommended for diagnosing lung infiltrates (LI) in patients with hematologic malignancy (HM). Prospective data on the impact of BAL on survival are still lacking. We conducted a prospective observational study on patients who performed BAL for LI among 3055 HM patients hospitalized from January to September 2018. The BAL was performed in 145 out of 434 patients who developed LI, at a median time of four days from LI detection. The median age was 60 (1-83). Most patients had an acute myeloid leukemia/myelodisplastic syndrome (81), followed by lymphoma (41), acute lymphoblastic leukemia (27), and other types of HM (36). A putative causal agent was detected in 111 cases (76{\%}), and in 89 cases (61{\%}) the BAL results provided guidance to antimicrobial treatment. We observed a significantly improved outcome of LI at day +30 in patients who could receive a BAL-driven antimicrobial treatment (improvement/resolution rate: 71{\%} vs 55{\%}; P =.04). Moreover, we observed a significantly improved outcome in 120-day overall survival (120d-OS) (78{\%} vs 59{\%}; P =.009) and 120-day attributable mortality (120d-AM) (11{\%} vs 30{\%}; P = 0.003) for patients who could receive a BAL-driven treatment. The multivariate analysis showed that BAL-driven antimicrobial treatment was significantly associated with better 120d-OS and lower 120d-AM. We did not observe any severe adverse events. In conclusion BAL allows detection of a putative agent of LI in about 75{\%} of cases, it is feasible and well tolerated in most cases, demonstrating that a BAL-driven antimicrobial treatment allows improvement of clinical outcome and survival.",
author = "{on behalf of the Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group} and Francesco Marchesi and Chiara Cattaneo and Marianna Criscuolo and Mario Delia and Michelina Dargenio and {Del Principe}, {Maria Ilaria} and Antonio Spadea and Fracchiolla, {Nicola Stefano} and Lorella Melillo and Katia Perruccio and Caterina Alati and Domenico Russo and Mariagrazia Garzia and Marco Brociner and Mariagiovanna Cefalo and Daniele Armiento and Simone Cesaro and Nunzia Decembrino and Andrea Mengarelli and Mario Tumbarello and Alessandro Busca and Livio Pagano",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ajh.25585",
language = "English",
volume = "94",
pages = "1104--1112",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates

T2 - A prospective multicenter study of the SEIFEM group

AU - on behalf of the Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group

AU - Marchesi, Francesco

AU - Cattaneo, Chiara

AU - Criscuolo, Marianna

AU - Delia, Mario

AU - Dargenio, Michelina

AU - Del Principe, Maria Ilaria

AU - Spadea, Antonio

AU - Fracchiolla, Nicola Stefano

AU - Melillo, Lorella

AU - Perruccio, Katia

AU - Alati, Caterina

AU - Russo, Domenico

AU - Garzia, Mariagrazia

AU - Brociner, Marco

AU - Cefalo, Mariagiovanna

AU - Armiento, Daniele

AU - Cesaro, Simone

AU - Decembrino, Nunzia

AU - Mengarelli, Andrea

AU - Tumbarello, Mario

AU - Busca, Alessandro

AU - Pagano, Livio

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bronchoalveolar lavage (BAL) is recommended for diagnosing lung infiltrates (LI) in patients with hematologic malignancy (HM). Prospective data on the impact of BAL on survival are still lacking. We conducted a prospective observational study on patients who performed BAL for LI among 3055 HM patients hospitalized from January to September 2018. The BAL was performed in 145 out of 434 patients who developed LI, at a median time of four days from LI detection. The median age was 60 (1-83). Most patients had an acute myeloid leukemia/myelodisplastic syndrome (81), followed by lymphoma (41), acute lymphoblastic leukemia (27), and other types of HM (36). A putative causal agent was detected in 111 cases (76%), and in 89 cases (61%) the BAL results provided guidance to antimicrobial treatment. We observed a significantly improved outcome of LI at day +30 in patients who could receive a BAL-driven antimicrobial treatment (improvement/resolution rate: 71% vs 55%; P =.04). Moreover, we observed a significantly improved outcome in 120-day overall survival (120d-OS) (78% vs 59%; P =.009) and 120-day attributable mortality (120d-AM) (11% vs 30%; P = 0.003) for patients who could receive a BAL-driven treatment. The multivariate analysis showed that BAL-driven antimicrobial treatment was significantly associated with better 120d-OS and lower 120d-AM. We did not observe any severe adverse events. In conclusion BAL allows detection of a putative agent of LI in about 75% of cases, it is feasible and well tolerated in most cases, demonstrating that a BAL-driven antimicrobial treatment allows improvement of clinical outcome and survival.

AB - Bronchoalveolar lavage (BAL) is recommended for diagnosing lung infiltrates (LI) in patients with hematologic malignancy (HM). Prospective data on the impact of BAL on survival are still lacking. We conducted a prospective observational study on patients who performed BAL for LI among 3055 HM patients hospitalized from January to September 2018. The BAL was performed in 145 out of 434 patients who developed LI, at a median time of four days from LI detection. The median age was 60 (1-83). Most patients had an acute myeloid leukemia/myelodisplastic syndrome (81), followed by lymphoma (41), acute lymphoblastic leukemia (27), and other types of HM (36). A putative causal agent was detected in 111 cases (76%), and in 89 cases (61%) the BAL results provided guidance to antimicrobial treatment. We observed a significantly improved outcome of LI at day +30 in patients who could receive a BAL-driven antimicrobial treatment (improvement/resolution rate: 71% vs 55%; P =.04). Moreover, we observed a significantly improved outcome in 120-day overall survival (120d-OS) (78% vs 59%; P =.009) and 120-day attributable mortality (120d-AM) (11% vs 30%; P = 0.003) for patients who could receive a BAL-driven treatment. The multivariate analysis showed that BAL-driven antimicrobial treatment was significantly associated with better 120d-OS and lower 120d-AM. We did not observe any severe adverse events. In conclusion BAL allows detection of a putative agent of LI in about 75% of cases, it is feasible and well tolerated in most cases, demonstrating that a BAL-driven antimicrobial treatment allows improvement of clinical outcome and survival.

UR - http://www.scopus.com/inward/record.url?scp=85070247895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070247895&partnerID=8YFLogxK

U2 - 10.1002/ajh.25585

DO - 10.1002/ajh.25585

M3 - Article

C2 - 31321791

AN - SCOPUS:85070247895

VL - 94

SP - 1104

EP - 1112

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 10

ER -